Leukemia Fusion Genes (Q55) Screening Kit is a qualitative multiplex test for detection of 52 fusion genes resulting from chromosome translocations associated with chronic and acute leukemias, along with leukemia-related genes EVI1, HOX11 and HOX11L2 (see Table 1). All the 52 fusion genes include more than 182 clinically relevant chromosomal breakpoints. The kit detects RNA transcripts of fusion genes extracted from human bone marrow or peripheral whole blood samples using a RT-qPCR procedure. The results of the kit allow professionals to be more aware of the patient`s prognosis and provides professionals important insights into the treatment planning.

Principle

Leukemia Fusion Genes (Q55) Screening Kit is a multiplex RT-qPCR based assay for detection of the 55 leukemia-associated genes transcripts including EVI1, HOX11, HOX11L2 and 52 fusion genes in total RNA from human bone marrow or peripheral whole blood samples. Included in the kit are RT reaction mix and qPCR mix. cDNA is synthesized by adding purified total RNA to the RT reaction mix prepared in advance. The resulting cDNA is added to 12 qPCR reaction tubes, which contain specific PCR primers and probes for detection of the 55 leukemia-associated genes and an internal control gene of GUSB.

The qPCR is performed in a real-time thermal cycler with optical filters for the detection of FAM, ROX, HEX and Cy5 fluorescence signals. Amplification plots and the resulting Cq (quantification cycle) values are used for the identification of the 55 leukemia-associated genes transcript.

CE-IVD Marked